NeuroOne Medical Technologies Corporation Common Stock (NMTC) is a publicly traded Healthcare sector company. As of May 21, 2026, NMTC trades at $4.09 with a market cap of $39.05M and a P/E ratio of -44.56. NMTC moved +0.00% today. Year to date, NMTC is -19.70%; over the trailing twelve months it is +9.66%. Its 52-week range spans $2.37 to $8.34. Analyst consensus is strong buy with an average price target of $9.67. Rallies surfaces NMTC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NeuroOne Q2 Loss Widens to $11.2M While Cash Fuels Mid-2026 Pilot Study: NeuroOne posted a fiscal Q2 net loss of $11.2 million on revenue of $0.4 million, compared with a $7.1 million loss and $0.3 million in the year-ago period. Cash and equivalents totaled $23.5 million as of March 31, funding ongoing R&D and preparations for a mid-2026 pilot study of its neurovascular access device.
| Metric | Value |
|---|---|
| Price | $4.09 |
| Market Cap | $39.05M |
| P/E Ratio | -44.56 |
| EPS | $-0.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.34 |
| 52-Week Low | $2.37 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $9.10M |
| Net Income | $-3.61M |
| Gross Margin | 56.51% |
3 analysts cover NMTC: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.67.